GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 23, 2003. The report primarily details corporate actions regarding share repurchases and changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADS).

Key Financial Metrics

The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:

• Share Repurchase: 1,150,000 Ordinary 25 pence shares purchased for cancellation on December 18, 2003, at 1,268.8 pence per share.
• ADS Conversion and Sale: 999,000 Ordinary shares converted into 499,500 ADS, subsequently sold at US$45.23 per ADS.
• Trust Purchases: The GSK US Trust purchased 499,500 ADS at US$45.23 per ADS.
• Director Acquisitions: Various directors acquired small numbers of Ordinary Shares via Personal Equity Plans at approximately £12.57 per share.

Material Changes

The filing reports specific changes in share ownership structures rather than operational performance changes:

• Capital Reduction: The company reduced its share count by 1,150,000 shares through a buyback for cancellation.
• Trust Movements: The GlaxoSmithKline US Retirement Savings Plan saw fluctuations in holdings, decreasing from 18,764,201 to 18,698,529 ADRs on December 17, and increasing to 18,727,604 ADRs by December 19.
• Employee Plan Transfers: Shares were transferred from the GSK Trust and SmithKline Beecham Employee Benefit Trust to participants in various employee share option and investment plans.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. The document is strictly a notification of regulatory compliance regarding share transactions and director interests.

Investor Verification Checklist

• Verify the total cost of the 1,150,000 share repurchase and its impact on the company's cash position.
• Confirm the aggregate number of shares held by the GSK Trust and GSK US Trust following the reported conversions and transfers.
• Review the full Annual Report (Form 20-F) for comprehensive financial performance data, as this 6-K does not contain revenue or earnings figures.
• Check subsequent filings for any further changes in director interests or share buyback programs.